Guilford Street Labs

Guilford Street Laboratories uses mass spectrometry and multi-omics to turn rare disease biomarkers into minimally invasive blood and urine tests. Work spans Fabry disease, lysosomal storage disorders and congenital disorders of glycosylation, plus HCM Predict, an FDA Breakthrough blood panel for hypertrophic cardiomyopathy. Team includes Dr Wendy Heywood and CSO Prof Kevin Mills.